[HTML][HTML] Cannabinoid treatment for autism: a proof-of-concept randomized trial
A Aran, M Harel, H Cassuto, L Polyansky, A Schnapp… - Molecular autism, 2021 - Springer
Background Endocannabinoid dysfunction in animal models of autism spectrum disorder
(ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this …
(ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this …
Cannabinoid treatment for autism: a proof-of-concept randomized trial.
A Aran, M Harel, H Cassuto, L Polyansky… - Molecular …, 2021 - europepmc.org
Background Endocannabinoid dysfunction in animal models of autism spectrum disorder
(ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this …
(ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this …
Cannabinoid treatment for autism: a proof-of-concept randomized trial.
A Aran, M Harel, H Cassuto, L Polyansky… - Molecular …, 2021 - search.ebscohost.com
Background: Endocannabinoid dysfunction in animal models of autism spectrum disorder
(ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this …
(ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this …
[HTML][HTML] Cannabinoid treatment for autism: a proof-of-concept randomized trial
A Aran, M Harel, H Cassuto, L Polyansky… - Molecular …, 2021 - ncbi.nlm.nih.gov
Background Endocannabinoid dysfunction in animal models of autism spectrum disorder
(ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this …
(ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this …
Cannabinoid treatment for autism: a proof-of-concept randomized trial.
A Aran, M Harel, H Cassuto, L Polyansky… - Molecular …, 2021 - go.gale.com
Background Endocannabinoid dysfunction in animal models of autism spectrum disorder
(ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this …
(ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this …
[PDF][PDF] Cannabinoid treatment for autism: a proof-of-concept randomized trial
A Aran, M Harel, H Cassuto, L Polyansky, A Schnapp… - 2021 - academia.edu
Background: Endocannabinoid dysfunction in animal models of autism spectrum disorder
(ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this …
(ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this …
[PDF][PDF] Cannabinoid treatment for autism: a proof-of-concept randomized trial
A Aran, M Harel, H Cassuto, L Polyansky, A Schnapp… - 2021 - scholar.archive.org
Background: Endocannabinoid dysfunction in animal models of autism spectrum disorder
(ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this …
(ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this …
Cannabinoid treatment for autism: a proof-of-concept randomized trial
A Aran, M Harel, H Cassuto, L Polyansky… - Molecular …, 2021 - search.proquest.com
Background Endocannabinoid dysfunction in animal models of autism spectrum disorder
(ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this …
(ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this …
Cannabinoid treatment for autism: a proof-of-concept randomized trial
A Aran, M Harel, H Cassuto, L Polyansky, A Schnapp… - 2021 - pubmed.ncbi.nlm.nih.gov
Background Endocannabinoid dysfunction in animal models of autism spectrum disorder
(ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this …
(ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this …
[HTML][HTML] Cannabinoid treatment for autism: a proof-of-concept randomized trial
A Aran, M Harel, H Cassuto… - Molecular …, 2021 - molecularautism.biomedcentral.com
Endocannabinoid dysfunction in animal models of autism spectrum disorder (ASD) and
accumulating, albeit anecdotal, evidence for efficacy in humans motivated this placebo …
accumulating, albeit anecdotal, evidence for efficacy in humans motivated this placebo …